Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):176-7. doi: 10.1007/s00259-013-2603-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Female
  • Humans
  • Intestinal Neoplasms / radiotherapy*
  • Male
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Organometallic Compounds / therapeutic use*
  • Pancreatic Neoplasms / radiotherapy*
  • Radiopharmaceuticals / therapeutic use*
  • Somatostatin / analogs & derivatives*
  • Stomach Neoplasms / radiotherapy*

Substances

  • Organometallic Compounds
  • Radiopharmaceuticals
  • Somatostatin
  • Octreotide